Athos KG

Overview

Athos KG is a family office established by German entrepreneurs Thomas and Andreas Strüngmann, renowned for their significant contributions to the healthcare and biotechnology sectors. The Strüngmann brothers co-founded Hexal AG, a leading generic drug manufacturer, which was sold to Novartis in 2005 for $6.7 billion. Building upon this success, they established their family office to manage their wealth and continue their investment endeavors in the life sciences industry. The family office employs a diversified investment strategy, allocating capital across private and public markets, real assets, and direct investments. Their focus spans various stages of company development, including early-stage ventures, growth-stage companies, late-stage investments, pre-IPO opportunities, and buyouts. This approach enables them to support a wide range of companies within the healthcare and biotechnology sectors, from innovative startups to established industry leaders. Athos KG's investment philosophy is centered on long-term value creation, emphasizing sustainable growth and the advancement of groundbreaking technologies in the life sciences. Their portfolio includes a variety of companies involved in pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health, reflecting their commitment to enhancing healthcare outcomes and driving innovation in the sector.

Investment Focus

• Strong management teams
• Innovative technologies
• Scalable business models
• Potential for significant impact in the healthcare sector
• Alignment with long-term value creation objectives

Portfolio Companies